Health and Healthcare
As Stent Business Falls Apart, Field Gets More Crowded
Published:
Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns about whether the product has long-term risks or whether it is more effective than drug treatments.
Stents, the little metal supports that keep blocked arteries open, have come under whithering criticism in the medical community. The negative press has almost ruined the business for Boston Scientific (BSX) and Johnson & Johnson (JNJ) BSX, which relies heavily on the product has watched its stock fall from $27 in December 2005 to its current level below $15.
The stent companies hoped that if they coated their products with drugs that would prevent clotting where they were installed, it would help. It does not appear to have worked out that way.
This much is for certain. As demand for stents slackens, the number of players in the market is moving up.
Douglas A. McIntyre
Retirement planning doesn’t have to feel overwhelming. The key is finding professional guidance—and we’ve made it easier than ever for you to connect with the right financial advisor for your unique needs.
Here’s how it works:
1️ Answer a Few Simple Questions
Tell us a bit about your goals and preferences—it only takes a few minutes!
2️ Get Your Top Advisor Matches
This tool matches you with qualified advisors who specialize in helping people like you achieve financial success.
3️ Choose Your Best Fit
Review their profiles, schedule an introductory meeting, and select the advisor who feels right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.